1. Home
  2. PROF vs PBYI Comparison

PROF vs PBYI Comparison

Compare PROF & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PROF
  • PBYI
  • Stock Information
  • Founded
  • PROF N/A
  • PBYI 2010
  • Country
  • PROF Canada
  • PBYI United States
  • Employees
  • PROF N/A
  • PBYI N/A
  • Industry
  • PROF Medical/Dental Instruments
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PROF Health Care
  • PBYI Health Care
  • Exchange
  • PROF Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • PROF 149.7M
  • PBYI 171.7M
  • IPO Year
  • PROF N/A
  • PBYI N/A
  • Fundamental
  • Price
  • PROF $5.50
  • PBYI $5.17
  • Analyst Decision
  • PROF Strong Buy
  • PBYI Strong Buy
  • Analyst Count
  • PROF 1
  • PBYI 1
  • Target Price
  • PROF $11.00
  • PBYI $7.00
  • AVG Volume (30 Days)
  • PROF 28.5K
  • PBYI 604.0K
  • Earning Date
  • PROF 08-14-2025
  • PBYI 08-07-2025
  • Dividend Yield
  • PROF N/A
  • PBYI N/A
  • EPS Growth
  • PROF N/A
  • PBYI 434.29
  • EPS
  • PROF N/A
  • PBYI 0.97
  • Revenue
  • PROF $11,862,000.00
  • PBYI $238,062,000.00
  • Revenue This Year
  • PROF $63.99
  • PBYI N/A
  • Revenue Next Year
  • PROF $117.19
  • PBYI N/A
  • P/E Ratio
  • PROF N/A
  • PBYI $5.05
  • Revenue Growth
  • PROF 75.01
  • PBYI 8.63
  • 52 Week Low
  • PROF $3.90
  • PBYI $2.23
  • 52 Week High
  • PROF $9.87
  • PBYI $5.06
  • Technical
  • Relative Strength Index (RSI)
  • PROF 47.57
  • PBYI 84.56
  • Support Level
  • PROF $5.49
  • PBYI $3.05
  • Resistance Level
  • PROF $5.96
  • PBYI $5.06
  • Average True Range (ATR)
  • PROF 0.27
  • PBYI 0.28
  • MACD
  • PROF 0.01
  • PBYI 0.21
  • Stochastic Oscillator
  • PROF 46.83
  • PBYI 93.05

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: